Hematology
From the Journals
Post–COVID vaccine AHA cases raise eyebrows in Italy
Four cases of acquired hemophilia A that occurred following COVID-19 vaccinations in one Italian province could indicate “possible complications...
From the Journals
Endometriosis not linked with preterm birth, new study finds
Changing monitoring strategies to prevent preterm birth for women with the disease may not be necessary.
From the Journals
Stopping venetoclax treatment early reduces CLL survival outcomes
Survival outcomes are decreased with early, permanent discontinuation of venetoclax but unchanged by treatment interruption, regardless of...
Latest News
Prophylactic meds may prevent cesarean bleeding
“As methylergonovine is a known contraindication to hypertensive and cardiovascular disorders, patients would have to be carefully screened.”
News
FDA approves first-ever drug for cold agglutinin disease
The first drug to treat a rare anemia has been given the green light by the FDA.
From the Journals
CLL patients ‘cured’: 10 years post infusion, CAR T cells persist
A decade after CAR T’cell treatment, chronic leukemia patients reported “cured,” with cells still detectable.
Latest News
Digital algorithm better predicts risk for postpartum hemorrhage
By more precisely identifying women at risk, the new method “could be used to pre-emptively allocate resources that can ultimately reduce...
Feature
Rituximab and COVID-19 vaccines: Studies begin to answer key questions
This article aims to summarize the latest research on how rituximab affects humoral and cell-mediated response following a COVID-19 vaccine...
Feature
DKMS: Small nonprofit to world’s largest stem cell donor registry
A German family’s tragedy launched DKMS, a multinational organization whose goal is to “delete blood cancer.”
Feature
CVS Caremark formulary change freezes out apixaban
The decision doesn’t affect patients on a Medicare or Medicaid plan but hits those taking the popular anticoagulant who have select commercial...
From the Journals
‘Highly encouraging’ MRD results for zanubrutinib add-on in CLL
Blood and bone marrow MRD was undetectable in almost 90% of subjects after a median of 10 treatment cycles.